Celltrion Healthcare sells Remsima exclusively in Libya and Tunisia

As winning the bidding competition for infliximab biosimilar in the Middle Eastern countries, Celltrion Healthcare started to exclusively sell ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease.

Celltrion Healthcare succeeded in winning a tender against the original product at the infliximab bidding for the Middle Eastern countries held in Libya and Tunis...